Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 69

1.

The use of permutation tests for the analysis of parallel and stepped-wedge cluster-randomized trials.

Wang R, De Gruttola V.

Stat Med. 2017 May 2. doi: 10.1002/sim.7329. [Epub ahead of print]

PMID:
28464567
2.

Brief Report: Changes in Levels of Inflammation After Antiretroviral Treatment During Early HIV Infection in AIDS Clinical Trials Group Study A5217.

Macatangay BJ, Yang M, Sun X, Morton J, De Gruttola V, Little S, Hogan C, Rinaldo CR; A5217 Team..

J Acquir Immune Defic Syndr. 2017 May 1;75(1):137-141. doi: 10.1097/QAI.0000000000001320.

PMID:
28198712
3.

Leveraging contact network structure in the design of cluster randomized trials.

Harling G, Wang R, Onnela JP, De Gruttola V.

Clin Trials. 2017 Feb;14(1):37-47. doi: 10.1177/1740774516673355. Epub 2016 Oct 24.

PMID:
27798376
4.

Reply to Cohen et al.

Oldenburg CE, Bärnighausen T, Tanser F, Iwuji CC, De Gruttola V, Seage GR 3rd, Mimiaga MJ, Mayer KH, Pillay D, Harling G.

Clin Infect Dis. 2016 Dec 15;63(12):1680. Epub 2016 Sep 29. No abstract available.

PMID:
27694482
5.

Antiretroviral Therapy to Prevent HIV Acquisition in Serodiscordant Couples in a Hyperendemic Community in Rural South Africa.

Oldenburg CE, Bärnighausen T, Tanser F, Iwuji CC, De Gruttola V, Seage GR 3rd, Mimiaga MJ, Mayer KH, Pillay D, Harling G.

Clin Infect Dis. 2016 Aug 15;63(4):548-54. doi: 10.1093/cid/ciw335. Epub 2016 May 20.

6.

Viral Genetic Linkage Analysis in the Presence of Missing Data.

Liu SH, Erion G, Novitsky V, De Gruttola V.

PLoS One. 2015 Aug 24;10(8):e0135469. doi: 10.1371/journal.pone.0135469. eCollection 2015.

7.

Sampling dynamic networks with application to investigation of HIV epidemic drivers.

Goyal R, De Gruttola V.

Math Biosci. 2015 Sep;267:124-33. doi: 10.1016/j.mbs.2015.06.013. Epub 2015 Jul 19.

8.

Sampling Networks from Their Posterior Predictive Distribution.

Goyal R, De Gruttola V, Blitzstein J.

Netw Sci (Camb Univ Press). 2014 Apr 1;2(1):107-131.

9.

Psychosocial predictors of non-adherence and treatment failure in a large scale multi-national trial of antiretroviral therapy for HIV: data from the ACTG A5175/PEARLS trial.

Safren SA, Biello KB, Smeaton L, Mimiaga MJ, Walawander A, Lama JR, Rana A, Nyirenda M, Kayoyo VM, Samaneka W, Joglekar A, Celentano D, Martinez A, Remmert JE, Nair A, Lalloo UG, Kumarasamy N, Hakim J, Campbell TB; PEARLS (ACTG A5175) Study Team..

PLoS One. 2014 Aug 25;9(8):e104178. doi: 10.1371/journal.pone.0104178. eCollection 2014.

10.

Sample size considerations in the design of cluster randomized trials of combination HIV prevention.

Wang R, Goyal R, Lei Q, Essex M, De Gruttola V.

Clin Trials. 2014 Jun;11(3):309-318. doi: 10.1177/1740774514523351.

11.

FLEXIBLE COVARIATE-ADJUSTED EXACT TESTS OF RANDOMIZED TREATMENT EFFECTS WITH APPLICATION TO A TRIAL OF HIV EDUCATION.

Stephens AJ, Tchetgen Tchetgen EJ, De Gruttola V.

Ann Appl Stat. 2013 Dec 23;7(4):2106-2137.

12.

Locally efficient estimation of marginal treatment effects when outcomes are correlated: is the prize worth the chase?

Stephens A, Tchetgen Tchetgen E, De Gruttola V.

Int J Biostat. 2014;10(1):59-75. doi: 10.1515/ijb-2013-0031.

13.

Linkage of viral sequences among HIV-infected village residents in Botswana: estimation of linkage rates in the presence of missing data.

Carnegie NB, Wang R, Novitsky V, De Gruttola V.

PLoS Comput Biol. 2014 Jan;10(1):e1003430. doi: 10.1371/journal.pcbi.1003430. Epub 2014 Jan 9.

14.

Changes in HIV-1 subtypes B and C genital tract RNA in women and men after initiation of antiretroviral therapy.

Fiscus SA, Cu-Uvin S, Eshete AT, Hughes MD, Bao Y, Hosseinipour M, Grinsztejn B, Badal-Faesen S, Dragavon J, Coombs RW, Braun K, Moran L, Hakim J, Flanigan T, Kumarasamy N, Campbell TB; A5185s Team..

Clin Infect Dis. 2013 Jul;57(2):290-7. doi: 10.1093/cid/cit195. Epub 2013 Mar 26.

15.

A general implementation of TMLE for longitudinal data applied to causal inference in survival analysis.

Stitelman OM, De Gruttola V, van der Laan MJ.

Int J Biostat. 2012 Sep 18;8(1). pii: /j/ijb.2012.8.issue-1/1557-4679.1334/1557-4679.1334.xml. doi: 10.1515/1557-4679.1334.

PMID:
22992289
16.

T cell activation markers and African mitochondrial DNA haplogroups among non-Hispanic black participants in AIDS clinical trials group study 384.

Hulgan T, Robbins GK, Kalams SA, Samuels DC, Grady B, Shafer R, Murdock DG, Selph D, Haas DW, Pollard RB; AIDS Clinical Trials Group..

PLoS One. 2012;7(8):e43803. doi: 10.1371/journal.pone.0043803. Epub 2012 Aug 27.

17.

Efficacy and safety of three antiretroviral regimens for initial treatment of HIV-1: a randomized clinical trial in diverse multinational settings.

Campbell TB, Smeaton LM, Kumarasamy N, Flanigan T, Klingman KL, Firnhaber C, Grinsztejn B, Hosseinipour MC, Kumwenda J, Lalloo U, Riviere C, Sanchez J, Melo M, Supparatpinyo K, Tripathy S, Martinez AI, Nair A, Walawander A, Moran L, Chen Y, Snowden W, Rooney JF, Uy J, Schooley RT, De Gruttola V, Hakim JG; PEARLS study team of the ACTG..

PLoS Med. 2012;9(8):e1001290. Epub 2012 Aug 14.

18.
19.

Using HIV transmission networks to investigate community effects in HIV prevention trials.

Wertheim JO, Kosakovsky Pond SL, Little SJ, De Gruttola V.

PLoS One. 2011;6(11):e27775. doi: 10.1371/journal.pone.0027775. Epub 2011 Nov 16.

20.

Mitochondrial genomics and CD4 T-cell count recovery after antiretroviral therapy initiation in AIDS clinical trials group study 384.

Grady BJ, Samuels DC, Robbins GK, Selph D, Canter JA, Pollard RB, Haas DW, Shafer R, Kalams SA, Murdock DG, Ritchie MD, Hulgan T; ACTG 384 and DACS 250 Study Teams..

J Acquir Immune Defic Syndr. 2011 Dec 1;58(4):363-70. doi: 10.1097/QAI.0b013e31822c688b.

Supplemental Content

Loading ...
Support Center